Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (NSQ-NSCLC) with PD-L1 high expression using real-world data

Cancer immunotherapy as monotherapy or combined with platinum-based chemotherapy is a first line treatment for patients with metastatic non-squamous non-small cell lung cancer with high PD-L1 expression. Real-world data are used to compare clinical outcomes with CIT-mono vs CIT-chemo, with analyses of poor prognostic baseline characteristics, median follow-up, median OS, and rwPFS reported.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

I am a healthcare professional

Not a healthcare professional? Browse:

Roche's patients website Roche.com

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically